Perspectives

WuXi Biologics published this article on industry media website BioProcess International discussing the need for multiple and regional drug substance (DS) and drug product (DP) manufacturing sites around the globe as a risk mitigation approach to ensure that the supply of biologics and vaccines is provided in a reproducible, reliable, timely and cost-effective manner. Although the utilization of a primary, single-location manufacturing site is often times the simplest and potentially most cost-effective strategy, the pandemic highlighted limitations to this approach leading to consequences in the availability of critical life-saving biologics and vaccines. By using a “Global Dual Sourcing” supply chain and offering multiple manufacturing sites around the world to its clients, WuXi Biologics addresses these concerns and regional manufacturing issues.

For this and other articles published on Bioprocess International, please check out this link.